During the pandemic years, many of us became acutely aware of our respiratory health, particularly in relation to how covid-19 could exacerbate pre-existing conditions. This morning, we kick things off with an exit in that very field, with Aksìa’s sale of an Italian spirometry company.
The IPO market has remained tepid for quite some time, but there might be some signs of light, based on figures from S&P Global Market Intelligence.
